Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$1.8 million.

  • Pharma's Income towards Parent Company fell 605.71% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year increase of 4871.51%. This contributed to the annual value of -$7.1 million for FY2025, which is 4522.31% up from last year.
  • As of Q3 2025, Pharma's Income towards Parent Company stood at -$1.8 million, which was down 605.71% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Pharma's Income towards Parent Company registered a high of -$1.2 million during Q1 2025, and its lowest value of -$6.5 million during Q1 2022.
  • Its 5-year average for Income towards Parent Company is -$2.8 million, with a median of -$2.4 million in 2021.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 16216.05% in 2021, then skyrocketed by 6727.5% in 2024.
  • Quarter analysis of 5 years shows Pharma's Income towards Parent Company stood at -$2.4 million in 2021, then grew by 5.54% to -$2.2 million in 2022, then crashed by 148.51% to -$5.6 million in 2023, then soared by 67.28% to -$1.8 million in 2024, then rose by 0.44% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.2 million during Q1 2025.